C
Concord Drugs Ltd
BSE:538965
Concord Drugs Ltd
BSE:538965
Price:
70.81
INR
-1.14%
Market Closed
Market Cap:
₹708.1m
Relative Value
The Relative Value of one CONCORD stock under the Base Case scenario is 56.35 INR. Compared to the current market price of 70.81 INR, Concord Drugs Ltd is Overvalued by 20%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CONCORD
Relative Value
Base Case
56.35
INR
Overvaluation 20%
C
Multiples Across Competitors
CONCORD Competitors Multiples
Concord Drugs Ltd Competitors
Concord Drugs Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
C
|
Concord Drugs Ltd
BSE:538965
|
708.1m INR | 1.5 | 165.9 | 16.7 | 25.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
879B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.4B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
256.6B CHF | 4.2 | 19.9 | 11.8 | 13.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.8B CHF | 5.4 | 21.6 | 13.3 | 17.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
222.9B GBP | 5.1 | 29.2 | 16.2 | 22.8 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
286.7B USD | 4.4 | 15.7 | 9.7 | 11.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.1B USD | 2.5 | 20.1 | 7.7 | 10.3 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.2B USD | 2.5 | 17.1 | 7.2 | 8.8 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
